Reduction of rheniumV oxo Schiff base complexes with triethylphosphine

MOspace/Manakin Repository

Breadcrumbs Navigation

Reduction of rheniumV oxo Schiff base complexes with triethylphosphine

Please use this identifier to cite or link to this item: http://hdl.handle.net/10355/2231

[-] show simple item record

dc.contributor.author Williams, Stephen A. en
dc.contributor.author Lane, Stephanie R., 1982- en
dc.contributor.author Sisay, Nebiat en
dc.contributor.author Jurisson, Silvia S. (Silvia Sabine) en
dc.date 2005 en
dc.date.accessioned 2009-08-13T19:18:30Z en
dc.date.available 2009-08-13T19:18:30Z en
dc.date.issued 2005 en
dc.identifier.uri http://hdl.handle.net/10355/2231 en
dc.description Abstract only available en
dc.description.abstract Pioneering techniques for therapeutic treatment of cancers involve targeting cancer sites with strong beta-emitting radionuclides, thereby destroying the cancer cells. This is achieved by coordinating the radioisotope to a very chemically stable environment and linking it to a specific biologically active targeting molecule, which interacts with particular cancer cells. Radioactive isotopes of rhenium possess characteristics of such a nuclide. The focus of our research is to investigate two possible pathways for the reaction of [ReOX(Schiff base)] with phosphine ligands, one a mono-substituted ReV complex and one a di-substituted ReIII complex. The preferred ReIII complex is lower in oxidation state and more kinetically inert or stable relative to ReV. For practical applications it is necessary to have an extremely stable in vivo radionuclide complex which can be conjugated to a suitable biological targeting agent. The rigid sal2phen ligand, where Sal2phen is a tetradentate Schiff base ligand, was investigated to determine if the ReIII could be synthesized from the ReV starting complex [ReVOCl(Sal2phen)]. [ReVOCl(Sal2phen)] was reacted with triethylphosphine (PEt3) in attempts to yield the ReIII complex trans-[ReIII(PEt3)2(Sal2phen)][X]. Previous work indicated that the strongly reducing and strongly nucleophilic PEt3 might yield the ReV product from [ReVOCl(Sal2phen)]. The synthesized coordinated complex was reacted with an quaternary ammonium salt, ammonium hexaflurophosphate (NH4PF6), to induce crystallization of target compound [ReIII(PEt3)2(Sal2phen)][PF6]. Preliminary 1H-NMR, 31P-NMR, and infrared spectroscopy spectra indicate the formation of cis-[ReVO(PPh3)(Sal2phen)][X]. FTIR shows the presence of the Rhenium oxo group; 31P-NMR and 1H-NMR indicate the presence of ReV and a 1:1 PEt3 : Sal2phen complex. Single crystal x-ray diffraction, mass spectroscopy, and elemental analysis are additional methods of characterization. en
dc.description.sponsorship NSF-REU/NIH Program in Radiochemistry en
dc.language en_US en
dc.language.iso en_US en
dc.publisher University of Missouri--Columbia. Office of Undergraduate Research en
dc.relation.ispartof 2005 Summer Undergraduate Research and Creative Achievements Forum (MU) en
dc.source.uri http://undergradresearch.missouri.edu/forums-conferences/abstracts/abstract-detail.php?abstractid= en
dc.subject therapeutic treatment of cancers en
dc.subject beta-emitting radionuclides en
dc.subject rheniumV oxo Schiff base complexes en
dc.title Reduction of rheniumV oxo Schiff base complexes with triethylphosphine en
dc.type Presentation en
dc.contributor.meetingname Summer Undergraduate Research and Creative Achievements Forum (2005 : University of Missouri--Columbia) en
dc.contributor.corporatename University of Missouri-Columbia. Office of Undergraduate Research en
dc.relation.ispartofcommunity University of Missouri-Columbia. Office of Undergraduate Research. Undergraduate Research and Creative Achievements Forum


This item appears in the following Collection(s)

[-] show simple item record